Purdue and Amneal OxyContin clash ends
15-08-2018
Purdue continues OxyContin patent battle
10-10-2017
Natee Meepian / iStockphoto.com
Purdue Pharma has settled another patent dispute involving pain drug OxyContin (oxycodone), just weeks after a suit against generics company Amneal Pharmaceuticals came to an end.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Purdue Pharma, Assertio Therapeutics, OxyContin, ANDA, FDA, patent, patent infringement, oxycodone, dismissal, Depomed
